

How to Cite:

Muthanna, F. M., Samad, A., Ibrahim, H. K., Al-Awkally, N.-A. M., & Sabir, S. (2022). Cancer related anaemia (CRA): An overview of approach and treatment. *International Journal of Health Sciences*, 6(S2), 2552–2558. <https://doi.org/10.53730/ijhs.v6nS2.5578>

Cancer related anaemia (CRA): An overview of approach and treatment

Fares M Muthanna

Department of Pharmaceutical Care, School of Pharmacy, Walailak University, Nakhon Si Thammarat, Thailand
Email: fariszaydi@gmail.com

Abdul Samad

Faculty of Veterinary and Animal Sciences, MNS University of Agriculture, 25000, Multan, Pakistan

Hamza Khaliha Ibrahim

Higher Institute of Medical Technology, Bani Waleed, Libya

Noor-Alhoda Milood Al-Awkally

Medical Laboratory Department, High Institute of Science and Technology, Suluvaq, Libya

Sidra Sabir

Faculty Of Health Sciences, Universiti Teknologi MARA Cawangan Selangor, Kampus Puncak Alam, Malaysia

Abstract--Cancer-related anemia (CRA) is a complicated and multifaceted problem that can occur as a result of tumor, as an adverse reaction of chemotherapeutic agent, or as a result of neurotoxic effects. The symptoms of CRA vary depending on an individual's response to blood loss or reduction in the number of red blood cell production. Patients with severe anemia have different characteristics depending on the type of haematological malignancy they have. Clinical and biochemical evaluations, as well as bone marrow examinations, may be useful diagnostic tools in many cases. Iron therapy can be used alone or in combination with ESA to improve the response of Hb and to decrease the need of RBC transfusion. Blood transfusion carries a number of risks, some of which can be mitigated or even eliminated. Even though erythropoietin-stimulating agents (ESAs) have been shown to be effective in preventing anemia and reducing the need for blood transfusions, it would be helpful for identifying high-risk patient groups that would benefit the most from these expensive treatments. Blood transfusions should be used on a

specific instance basic principle in patients with advanced cancer, depending on the extent of distressing symptoms and life expectancy.

Keywords--CRA, management, iron supplements, erythropoietin-stimulating agents.

Introduction

Anaemia is a medical condition that causes when the body's production of red blood cells (RBCs) is insufficient, as evidenced by a reduction of haemoglobin (Hb) or a decline in the packed cell volume (PCV) of RBCs when measured within specified range (1; 2). Anemia also is defined as Hb 11 g/dl or less than 2 g/dl below normal, according to the National Comprehensive Cancer Network (NCCN) guidelines. Furthermore, the World Health Organization describes anemia as a situation related to low level of hemoglobin (Hb) of 12 g per dL in females and 13 g per dL in male population. (3). Males have an average RBC count of 5.410⁶ cells per liter, while women have an average RBC count of 4.810⁶ cells per liter (4). CRA is a common side effect in individuals who have cancer at the initial diagnosis (5), and its growing incidence is associated with a decline in quality of life (6). It did not appear to be caused by multiple simultaneous efficient anticancer therapy, but rather by a reduction in tumor-related chronic inflammation (7). Metabolic and physiological characteristics of anemia are clearly comparable and directly linked with those explained with other symptomatic inflammatory diseases (8). Steadily increasing proinflammatory cytokines and tiredness are linked generally and specifically to CRA (9). CA anemia is cancer is characterized as a mild, hypochromic normocytic anemia with hemoglobin concentration range of 0 to 10 g/dL and significantly reduced circulatory serum ferritin accumulation and transferrin saturation (e.g., serum ferritin >100 ng/mL) despite normal iron stores.

What is the Prevalence of Anaemia in cancer ?

The severity of the risk of prevalence of anemia varies depending on the type of cancer (10). Barrett-Lee P et al, (2005) conducted a prior research in the European Union and found that 30.4 % and 49.1 % of participants admitted to hospital with breast and gynaecological tumor were anemic at the time of admission, respectively (11). A number of factors, including the sort of management, the sort of malignancy, and the tumor stage, influence the presence and incidence of anemia in cancer patients. Melanoma type, anemia concept (9 g/dL vs. 11 g/dL), and chemotherapy medication are all variables that impact epidemiology of anemia. As shown in an analysis of relevant literature published in 2004, the overall prevalence of CRA tend to range from 30 to 90%. (10). Furthermore, as shown in a new analysis, 41% of women with breast cancer in Malaysia have been anemic after undergoing neoadjuvant chemotherapy (11).

Pathophysiology and Aetiology of CRA

The etiopathogenesis causes of anemia can be grouped into three types: blood clot, Erythrocytes damage, and a reduction in the level of RBC production. (12);

10). Thrombosis irregularities, bleeding internally, haematuria, genetic factors, renal and hepatic deficits, poor nutrition (e.g. due to disordered eating behaviors or digestive neoplasms excision), inflammatory disorders, or a mixture of such approaches can all increase the likelihood and risk of cancer-related anemia (13; 14).

Intervention of cancer related anaemia (CRA)

The National Comprehensive Cancer Network (NCCN), the American Society of Cancer Oncology (ASCO), and the European Society of Medical Oncology (ESMO) all recommend treating anemia in cancer with or without iron therapy by tackling the causes of anemia or providing sufficient treatment, such as Erythrocytes transfusion or providing erythropoiesis-stimulating agents (ESAs). When the principal cause is absolute anaemia (ferritin 30 ng/mL, transferrin saturation 15%) or functional anaemia (ferritin 800 ng/mL, transferrin saturation 20%), both the NCCN and ESMO guidelines suggest nutritional and iron therapy once the Hb level drops below 10 g/dL (15: 16), the fundamental findings are inconsistent, or anaemia is associated with chronic clinical symptoms. Supplements combined with ESAs reduces necessity of blood transfusions, improves ESA effectiveness, and enhances the response of Hb. Red Blood Cells transfusion is highly suggested when Hb falls below 8 g/dL or when severe anemia complications arise (15; 16). In patients received EPO with or without iron deficiency, the ASCO/NIH guidelines suggest beginning iron supplementation to enhance response of Hb and reduce the need for red blood cells (RBC) transfusions.

ESAs, blood transfusions, and IV iron treatments all have advantages and disadvantages. Some of the symptoms of IV iron therapy include drowsiness, blurry vision, dyspepsia, anxiety, hypotension, hypertension, chest pain, skin disease, dizziness, and fatigue. The most significant advantage of incorporating iron supplements into ESAs is that it decrease the need for blood transfusions, helps to improve Hb threshold, and elevates ESA effectiveness. If anaemia is caused by absolute or functional iron - deficiency measures, ESAs and RBC transfusion are not recommended for boosting and adjusting Hemoglobin level unless the Haemoglobin level is less than 10 g/dL.

The Malaysian Clinical Practice Guideline (CPG) 2013 (17) states that treating anemia in patients receiving chemotherapy with blood products and ESAs can increase the risk of blood thrombosis. Hence, if intervention is initiated during Erythropoietin treatments, it should be prescribed. It is also recommended that i.v sucrose be used. RBC transfusion is a quick and easy therapeutic option that can dramatically improve a patient's status. (18: 6) by massively increasing haemoglobin levels (19). Red blood cell (RBC) transfusions are incredibly useful in extreme situations of symptomatic anaemia or life-threatening anaemia (Hb 7–8 g/dl). RBC transfusions must not be considered based on a particular Hb cutoff point, according to the recent National Comprehensive Cancer Network guidelines (18). They should instead be given to patients who have chronic and symptomatic anaemia, high-risk patients (e.g., those who have completed chemo- or radiotherapy and have an observable decrease in Hemoglobin level), or asymptomatic patients with severe situations, but not to people who have symptomatic alloantibodies. According to multiple studies, cancer patients who

prescribe with blood products have a better opportunity of living (19). Furthermore, blood transfusions can help individuals experiencing clinical cough and shortness of breath (20) and fatigue (21). Blood transfusions, on the other hand, pose significant severe and long-term risks, including fever, serious complications, infectious disease transmission, oxidative stress, and inflammatory diseases (22), and they have been connected to a growing venous thromboembolism hazard and death in hospitalized people (23).

The Food and Drug Administration (FDA) certified recombinant human erythropoietin (rHuEPO, epoetin alfa) in 1993 for the management of acute iron deficiency anemia in cancer patients. rHuEPO formulas are available in three varieties: r-HuEPOa, r-HuEPOb, and darbopoetin alpha. r-HuEPO has a longer half-life after subcutaneous administration due to its glucidic component than natural EPO, which has a half-life of 8.5 h (24 h for r-HuEPOa and 20.5 h for r-HuEPOb) (24). Numerous generic drug EPOs, including epoetin alfa, have recently been innovated into clinical research. In a large Cochrane meta-analysis that assessed ESAs for the management of CRA in people undergoing or not undergoing concurrent cancer treatment, rHuEPO has been shown to make a significant reduction in RBC blood products and an extremely high bone marrow response, thus improving health and quality of life, decreasing fatigue, and other specific anaemia-related clinical manifestations (25).

Various randomized controlled trials in people with advanced cancer and CRA discovered that ESAs ultimately results in an improved performance in patients' overall health, which was firmly correlated with elevated Hb levels (26). ESAs can also be helpful to one's wellbeing by acting as anti-inflammatory, cardiac, and metabolic stimulants (27). There is a great proof examined the efficacy of intravenous iron supplements, either alone or in combination with ESAs, in improving quality of life (6) and reducing the need for transfusion in cancer patients. Because of the absence of appropriate oral bioavailability, anabolic disruptions involved in immune signaling pathways, and digestive issues, oral iron supplements, which would be the first remedy for managing anaemia in patients with no infection, are ineffective for treating iron deficiency anemia caused by inflammation (28). When administered intravenously, iron, on the other hand, can be instantaneously stuck by neutrophils and macrophages, tackling absorption concerns. Saccharate iron ferric gluconate, like some other less stable structures, actually requires a few low dose infusions, whereas the more steady compounds, such as ferric carboxymaltose, allow for single injections of high iron doses that are well considered acceptable with a low incidence of severe allergic reactions (29). Nowadays, no pharmacological intervention is preferred; however, intravenous iron, whether in conjunction or not with ESAs, or transfusion, is highly recommended. (18). In the future, chelate-iron medicine, ferritin antagonists, and interleukins or hormonal imbalances that can adjust red blood cell production in severe autoimmune disorders could all be used. In any case, more investigations on people with cancer who are anemic is required.

Conclusions

More knowledge on the pathophysiology of cancer related anemia has been gathered in recent years, and more data on pharmacological interventions for CRA is emerging. However, a detailed clinical strategic approach for treating anemia in cancer that is related to a mixture treatment approaches and health and wellness therapies is still lacking. Regardless of the fact that it has already been found to significantly hamper intestinal microbiota and eventually cause gastrointestinal problems such as vomiting and morbidity, iron supplements is the mainstay of CRA therapies. Furthermore, this technique does not lead to a significant increase in the patient's consumption, particularly if the anaemia is not caused by oxidative stress in the first place. On the other hand, the findings show that a personalized dietary program based on the Balanced diet, properly participated in the process foods, and exercising or low-intensity daily exercise can drastically enhance patients' general health and impact their autoimmune reaction. The above-mentioned treatment plan was shown to reduce inflammatory reactions, which are the primary reason of cancer related anemia. More study is needed to find the appropriateness of the inclusive framework and to validate a working procedure in CRA.

References

1. Cheng K, Zhao F, Gao F, Dong H, Men H-T, Chen Y, et al (2012). Factors Potentially Associated with Chemotherapy-induced Anaemia in Patients with Solid Cancers. *Asian Pacific Journal of Cancer Prevention*; 13 (10):5057-5061.
2. Wan S, Lai Y, Myers RE, Li B, Palazzo JP, Burkart AL, et al (2013). Post-diagnosis haemoglobin change associates with overall survival of multiple malignancies – results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers. *BMC Cancer*; 13:341-351
3. World Health Organization. Cancer. 2017. <http://www.who.int/mediacentre/factsheets/fs297/en/>. Assessed 25 Apr 2017.
4. Pourali L, Taghizadeh A, Akhouni M R, Varshoei F, Zarifian A, et al (2017). Frequency of Chemotherapy Induced Anaemia in Breast Cancer Patients, *International Journal of Cancer Management*.; 10(1):e4672.
5. Madeddu, C., Gramignano, G., Astara, G., Demontis, R., Sanna, E., Atzeni, V., et al. (2018). Pathogenesis and Treatment Options of Cancer Related Anaemia: Perspective for a Targeted Mechanism-Based Approach. *Frontiers in physiology*, 9, 1294.
6. Fares Mohammed Saeed Muthanna, Bassam Abdul Rasool Hassan, Mahmathi Karuppannan, Ali Haider Mohammed, Evaluation of the impact of anaemia on quality of life among breast cancer patients undergoing chemotherapy in Malaysia. *Journal of Pharmaceutical Health Services Research*, Volume 12, Issue 2, June 2021, Pages 310–312, <https://doi.org/10.1093/jphsr/rmaa033>
7. Maccio, A.; Madeddu, C.; Gramignano, G.; Mulas, C.; Tanca, L.; Cherchi, M.C.; et al. (2015) . The role of inflammation, iron, and

- nutritional status in cancer-related anaemia : Results of a large, prospective, observational study. *Haematologica*, 100, 124–132.
8. Macciò, A., Madeddu, C., Gramignano, G., Mulas, C., Tanca, L., Cherchi, M. C., et al. (2015). The role of inflammation, iron, and nutritional status in cancer-related anaemia: results of a large, prospective, observational study. *Haematologica*, 100(1), 124–132.
 9. Muthanna, Fares Mohammed Saeed, Mahmathi Karuppannan, Bassam Abdul Rasool Hassan, and Ali Haider Mohammed. (2021). "Impact of fatigue on quality of life among breast cancer patients receiving chemotherapy." *Osong Public Health and Research Perspectives* 12, no. 2 : 115.
 10. Knight K, Wade S, Balducci L. (2004). Prevalence and outcomes of anaemia in cancer: A systematic review of the literature. *Am J Med*; 116: 11– 26.
 11. Muthanna, Fares MS, Mahmathi Karuppannan, Bassam Abdul Rasool Hassan, and Ali Haider Mohammed. "Assessment of Risk Factors Associated with Anaemia Severity among Breast Cancer Patients Undergoing Chemotherapy in Malaysia." *Systematic Reviews in Pharmacy* 11, no. 12 (2020): 2405-2411.
 12. Steegmann JL, Torres JMS , Colomer R, Vaz A , Lo´pez J , Jalo´n I, et al (2013). Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. *ClinTranslOncol*; 15:477–483
 13. Busti, F., Marchi, G., Ugolini, S., Castagna, A., & Girelli, D. (2018). Anaemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. *Pharmaceuticals (Basel, Switzerland)*, 11(4), 94.
 14. Dicato M, Plawny L, Diederich M (2010) . Anaemia in cancer .*Annals of Oncology* ;21: 167–172
 15. Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., & ESMO Guidelines Committee et al. (2018). Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. *Annals of oncology: official journal of the European Society for Medical Oncology*, 29(Suppl 4), iv96–iv110
 16. Bohlius, J., Bohlke, K., Castelli, R., Djulbegovic, B., Lustberg, M. B., Martino, M., et al. (2019). Management of Cancer-Associated Anaemia with 202 Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 37(15), 1336–1351.
 17. Choon, S., Chan, L., Choon, S. E., et al.. (2014). Malaysian Clinical Practice Guideline for the Management of Psoriasis Vulgaris: Summary of recommendations for management in primary healthcare setting. *Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia*, 9(1), 16–21.
 18. Rodgers, G.M.; Gilreath, J.A. (2019). The Role of Intravenous Iron in the Treatment of Anaemia Associated with Cancer and Chemo-therapy. *Acta Haematol.* 142, 13–20.
 19. Grogan, M.; Thomas, G.M.; Melamed, I.; Wong, F.L.; Pearcey, R.G.; Joseph, P.K.; Portelance, L.; Crook, J.; Jones, K.D (1999). The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. *Cancer*, 86, 1528–1536.

20. Mercadante, S.; Ferrera, P.; Villari, P.; David, F.; Giarratano, A.; Riina, S. (2009). Effects of red blood cell transfusion on anaemia -related symptoms in patients with cancer. *J. Palliat. Med.*, 12, 60–63.
21. Brown, E.; Hurlow, A.; Rahman, A.; Closs, S.J.; Bennett, M.I. (2010). Assessment of fatigue after blood transfusion in palliative care patients: A feasibility study. *J. Palliat. Med.*, 13, 1327–1330
22. Goodnough, L.T (2005). Risks of blood transfusion. *Anesthesiol. Clin. North. Am.*, 23, 241–252.
23. Khorana, A.A.; Francis, C.W.; Blumberg, N.; Culakova, E.; Refaai, M.A.; Lyman, G.H. (2008). Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. *Arch. Intern. Med.*, 168, 2377–2381.
24. Storrington, P.L.; Tiplady, R.J.; Gaines Das, R.E.; Stenning, B.E.; Lamikanra, A.; Rafferty, B.; Lee, J. (1998). Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. *Br. J. Haematol.* 100, 79–89.
25. Tonia, T.; Mettler, A.; Robert, N.; Schwarzer, G.; Seidenfeld, J.; Weingart, O.; Hyde, C.; Engert, A.; Bohlius, J. (2012). Erythropoietin or darbepoetin for patients with cancer. *Cochrane Database Syst. Rev.*, 12, Cd003407
26. Smith, R.E., Jr.; Aapro, M.S.; Ludwig, H.; Pintér, T.; Smakal, M.; Ciuleanu, T.E.; Chen, L.; Lillie, T.; Glaspy, J.A. (2008). Darbepoetin alpha for the treatment of anaemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. *J. Clin. Oncol.* 26, 1040–1050
27. Nekoui, A.; Blaise, G. Erythropoietin and Nonhematopoietic Effects. *Am. J. Med. Sci.* 2017, 353, 76–81.
28. Rodgers, G. M., Becker, P. S., Blinder, M., Cella, D., Chanan-Khan, A., Cleeland, C., Coccia, P. F., et al. (2012). Cancer- and chemotherapy-induced anaemia. *Journal of the National Comprehensive Cancer Network: JNCCN*, 10(5), 628–653.
29. Toblli, J.E.; Angerosa, M. (2014). Optimizing iron delivery in the management of anaemia : Patient considerations and the role of ferric carboxymaltose. *Drug Des. Dev. Ther.* 8, 2475–2491.